ABSTRACT Background: Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of MM (secondary PCL) and is characterized by circulating PCs >2×109/L in peripheral blood and a peripheral blood plasmacytosis >20%.
Introduction
Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral blood. [1] Diagnostic criteria for plasma cell leukemia are [2] : (1) Plasma cells >2×10 9 /L in peripheral blood; (2) Plasma cells >20% of blood leukocytes in peripheral blood; (3) Primary plasma cell leukaemia (pPCL): presents as de novo leukaemia; and (4) Secondary plasma cell leukemia (sPCL): progression from a preexisting multiple myeloma.
Altogether 60% of all PCL is pPCL. [3] Secondary PCL occurs as a progression of disease in 1 to 4% of all cases of MM, although it is now suspected to be a more common complication of patients exhibiting greater longevity. [4] There appears to be a 3:2 male to female sex distribution in both primary and secondary PCL. [5] The median age of diagnosis of pPCL is 55, a decade younger than the average age of MM diagnosis. [5] The median time to leukemic transformation for patients with MM who evolve to sPCL is 21 months. [5] Up to 15% of patients will have hepatomegaly, splenomegaly or lymphadenopathy due to extramedullary deposits of plasma cells. [4] Osteolytic lesions are more common in sPCL as they are also more common in preexisting MM (sPCL 53% vs. pPCL 18%). [5] Because of extensive involvement of the bone marrow patients with PCL have a higher prevalence of anaemia and thrombocytopenia. [5] [6] [7] Patients with pPCL present without a MM prodrome are characterized by higher prevalence of renal insufficiency and elevated β2-microglobulin as opposed to newly diagnosed MM. Patients with sPCL are also frequently afflicted with renal insufficiency. [5] Laboratory parameters of disease aggressiveness such as an elevated serum LDH or β2-microglobulin are common in PCL cases. [5, 7, 8] The most common proteins are of the IgG subtype (33%) followed by IgA (20%), IgD (3%) and IgE (1%). Notably 35% of patients do not produce a heavy chain (light chain only disease) and less than 10% will be nonsecretors. [5] Blood and bone marrow examination shows-Rouleux formation is most striking feature on PB smear examination .The morphological features of PCs can differ depending RESEARCH ARTICLE upon their maturity. Mature PCs are oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located and the chromatin arranged in pyramidal blocks against the nuclear membrane, giving the characteristic "cartwheel" appearance. Immature PCs have dispersed nuclear chromatin, prominent nucleoli and high nuclear to cytoplasmic ratio. The findings on bone marrow aspiration and biopsy are similar to those seen in MM without PCL and demonstrate an increased number of monoclonal PCs [9] The pattern of infiltration is mostly diffuse in all cases and this infiltration is able to disrupt normal hematopoiesis .
Immunophenotypic characteristics shows CD38 and CD138 antigen expression are excellent PC markers and does not differ between MM and PCL, while CD2, CD3 and CD16 are consistently negative. The frequency of CD10+, CD13+ and CD15+ is similar in both groups. Negative expression of CD56 has been associated with extramedullary MM. [7, 8, 10] Acquisition of the CD28 antigen on PCs appears to correlate with an increased proliferative rate and disease progression. [11] Differential diagnosis include B-cell chronic lymphocytic leukemia, hairy cell leukemia and marginal zonelymphomas with circulating lymphocytes. Rarely PCL needs to be differentiated from reactive polyclonal plasmacytosis related to infectious or autoimmune disorders. The majority of cases will be easily distinguished from other forms of leukemia and lymphoma by morphology with confirmation by flow cytometry or immunohistochemistry. Reactive polyclonal plasmacytosis can be excluded based upon absence of kappa or lambda light chain restriction. PCL is extremely aggressive associated with short survival; with treatment of only 7 to 11 months, with up to 28% of patients dying within the first month after diagnosis in different studies. [6, 5, 12] In general, patients are treated with aggressive induction therapy followed by HCT (haematopoietic stem cell transplantation) in those who are appropriate candidates for this approach. Chemotherapy alone is the principal option for those ineligible for HCT. Multi-agent infusional chemotherapy (e.g. vincristine, doxorubicin, plus dexamethasone) results in a superior, yet still poor median overall survival of approximately 15 to 18 months. [5, 7] Materials and Methods A large case study of 80 cases of Plasma cell leukemia was done by Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. [5] Genetic aberrations and survival in plasma cell leukemia, for important clinical & pathological features. We compared our study with study of Tiedemann et al. We compared main clinical and biological differences between primary PCL (p PCL) and secondary PCL (sPCL) of both studies. We analyze 7 cases of PCL.in present study with median age for pPCL was 53.2 years i.e. a decade younger than sPCL which was 68.1 years. It is comparable to previous study of Tiedemann et al in which it is 54.5 years in pPCL & 65.7 years in sPCL. In present study cases of splenomegaly were 25% & 33.33% in pPCL & sPCL respectively while in previous study they were 18% & 8% respectively. Cases of hepatomegaly in present study were 25% & 0% for pPCL & sPCL respectively while they were 32% & 11% in previous study. 
Conclusion
Plasma cells have characteristic morphological features which can be easily identified on peripheral blood & bone marrow examination.CD 38 & CD 138 are excellent plasma cell marker. Increased serum β2-microglobulin & serum LDH & decreased serum albumin are potent poor prognosis factor. PCL is aggressive neoplasm. Primary plasma cell leukaemia has a rapid course with short survival whereas the secondary form may be associated with a more indolent clinical course and survival is variable. Our observation indicates poor response to chemotherapy and poor prognosis of disease & low median survival time from diagnosis is seen in both types.
